ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of daily doses of RDC-0313 (ALKS 33)
compared with placebo in adults with binge-eating disorder (BED). An additional objective is
to explore the efficacy of RDC-0313 treatment in comparison with placebo in adults with
binge-eating disorder.